Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.

Authors :: Musto P
Fraticelli VL
Mansueto G
Madonna E
Nozza A
Andriani A
Mussetti A
Ballanti S
Bongarzoni V
Baraldi A
Patriarca F
Vincelli D
Falcone A
Derudas D
Califano C
Zambello R
Mele G
Fragasso A
Baldini L
Storti S
Source :: Leukemia & lymphoma [Leuk Lymphoma] 2015 May; Vol. 56 (5), pp. 1510-3. Date of Electronic Publication: 2015 Mar 03.
Publication Year :: 2015

Subjects :: Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bendamustine Hydrochloride administration & dosage
Female
Humans
Male
Middle Aged
Multiple Myeloma diagnosis
Multiple Myeloma mortality
Neoplasm Staging
Recurrence
Treatment Outcome
Antineoplastic Agents, Alkylating therapeutic use
Bendamustine Hydrochloride therapeutic use
Multiple Myeloma drug therapy
Multiple Myeloma pathology

Full Text Access

Tools